Clinical Pharmacology, Nonclinical and Translational Sciences, Allergan, Plc, 2525 Dupont Drive, Irvine, California, 92612, USA.
Ophthalmic Product Development, TWi Pharmaceuticals, Inc., Taipei, China.
Pharm Res. 2018 Sep 25;35(11):217. doi: 10.1007/s11095-018-2498-y.
The development of ophthalmic drug delivery systems is a long and comprehensive process including research, nonclinical, and clinical development stages. It is critical to understand the similarity and differences between animal models and patients. There are many anatomically and physiologically important parameters for targeted drug delivery into eyes. This paper reviews the constraints to various routes of ocular drug delivery and discusses the respective pharmacokinetic considerations, to lay the foundation for formulation approaches pharmaceutical scientists can use to maximize successful drug delivery for each route. The overall goal is to give both researchers and drug developers a better understanding of ocular drug delivery and offer tools to successfully develop new medicines that will fulfil unmet medical needs and improve patients' quality of life.
眼科药物传递系统的开发是一个漫长而全面的过程,包括研究、非临床和临床开发阶段。了解动物模型和患者之间的相似性和差异性非常重要。有许多针对眼部靶向药物传递的解剖学和生理学上重要的参数。本文综述了各种眼部药物传递途径的限制,并讨论了各自的药代动力学考虑因素,为药剂学家可以用来最大化每种途径的药物传递成功的制剂方法奠定基础。总体目标是让研究人员和药物开发者更好地了解眼部药物传递,并提供工具来成功开发新的药物,以满足未满足的医疗需求并提高患者的生活质量。